Alcohol use disorder affects tens of millions of people worldwide, yet the number of approved medications to treat it remains small. Researchers are now looking in an unexpected direction: a class of peptides called GLP-1 analogues, which mimic a gut hormone that regulates appetite and blood sugar. A recruiting phase-2 trial listed in the federal clinical-trials registry is testing whether a weekly subcutaneous injection of a GLP-1 analogue can reduce alcohol consumption in people diagnosed with the disorder.
The trial record, registered under identifier NCT06015893, describes a pilot proof-of-concept study that combines standard outpatient treatment with experimental human-laboratory procedures. The research team wants to know two things first: is the peptide safe and tolerable in this population, and does it meaningfully reduce how much participants drink? Everything else the study will measure flows from those two questions.
What GLP-1 analogues are
GLP-1 stands for glucagon-like peptide-1, a hormone the intestine releases after a meal. It signals the pancreas, the stomach, and the brain, slowing gastric emptying, reducing appetite, and influencing how the brain processes reward. Synthetic versions of this hormone, called GLP-1 analogues, have been researched extensively in the context of blood-sugar regulation and body weight.
The peptide studied in this trial is a long-acting GLP-1 analogue given by subcutaneous injection once a week. The trial record targets a dose of 2.4 mg per week, or the maximum tolerated dose for participants who cannot reach that level. Researchers chose this dose range because it is the same range studied in published weight-related trials, which means existing safety data can serve as a useful reference point.
Why researchers think GLP-1 signaling may affect alcohol intake
The rationale connecting a metabolic peptide to drinking behavior comes from preclinical and early human observations. GLP-1 receptors are distributed not just in the gut and pancreas but also in brain regions involved in reward and motivation, including areas that respond to alcohol. Animal studies have shown that activating these receptors can reduce voluntary alcohol intake, and a handful of small human studies have reported similar signals.
The hypothesis is that the same receptor activity that blunts food-related reward may also blunt alcohol-related reward or craving. The STAR trial is designed to test that hypothesis rigorously in a controlled outpatient setting, with enough participants and biomarker tracking to tell whether an early efficacy signal is real or noise.
Trial design and what gets measured
The study is described in the registry as a phase-2a, pilot, outpatient trial combined with experimental medicine human-laboratory procedures. Phase 2a means it is an early-stage efficacy and safety test, not a large confirmatory study. The pilot label signals that the investigators are gathering data to power a larger trial if results are promising.
The primary outcome is straightforward: total standard drinks consumed per week, measured from a baseline period to the end of treatment. Researchers will track this as drinks per week, a unit that makes statistical comparisons clean and clinically interpretable. Safety will be assessed by the frequency and severity of adverse events and by the proportion of participants who successfully reach the target weekly dose.
Secondary outcomes are broader. The trial will look at heavy drinking days, drinks per drinking day, and World Health Organization drinking-level categories. It will also measure phosphatidylethanol, abbreviated PEth, in blood samples. PEth is a direct biomarker of alcohol exposure that accumulates in red blood cells and does not depend on self-report, so it adds an objective check on what participants describe about their own drinking.
The laboratory cue-reactivity component
One of the more unusual features of the STAR trial is its use of two experimental laboratory environments. The first is a bar-like setting where researchers expose participants to alcohol-related cues and measure craving responses. Cue-elicited craving, the urge that arises when a person sees or smells alcohol-associated stimuli, is a recognized driver of relapse. If the peptide reduces this response, that would hint at a central nervous system mechanism rather than just a peripheral metabolic one.
The second environment is a virtual-reality buffet designed to capture food choices and food-related behavior. Because GLP-1 analogues are known to change appetite and food preference in other research contexts, the investigators want to track whether changes in eating patterns accompany any changes in drinking. This parallel measurement could help researchers understand whether the two effects share a mechanism or arise separately.
What the trial can and cannot tell us
A phase-2a pilot trial is intentionally limited in scope. It is not designed to prove that the peptide works as a treatment; it is designed to provide enough signal, positive or negative, to justify the cost of a larger study. That means the STAR trial's results will be informative but not definitive. If the primary outcome moves in the expected direction and adverse events are manageable, a phase-3 trial would be needed before any conclusions about clinical utility could be drawn.
The trial record also notes that participants receive something called Take Control alongside the peptide. This appears to be a behavioral support component, which means any observed reduction in drinking cannot be attributed to the peptide alone unless the study includes a proper control arm. The registry description does not detail the full randomization design, so readers interested in methodology would need to consult the full protocol.
Early data from this and similar trials will add to a growing body of literature on GLP-1 receptor signaling outside of metabolic contexts. Whether the peptide proves useful for alcohol use disorder or not, the mechanistic data the study collects about craving, biomarkers, and food behavior will be valuable for researchers designing the next generation of studies.
Where research on GLP-1 and addiction stands broadly
The STAR trial is not the only investigation in this space. Multiple research groups across several countries are examining GLP-1 analogues for their potential effects on addictive behavior, including nicotine and opioid use in addition to alcohol. The mechanistic logic is similar across substances: GLP-1 receptors in reward circuits may modulate the reinforcing properties of various stimuli, not just food.
Researchers caution that the animal models driving much of this interest do not always translate to humans, and that dose, timing, and individual variation in receptor expression could all affect outcomes. The literature is promising but early. Trials like STAR are the necessary next step, moving observations from animal studies and case reports into the more demanding environment of randomized human research where safety, tolerability, and real-world drinking behavior can all be tracked together.
